Alzamend Neuro Inc. (ALZN) Price to Earnings Ratio
Alzamend Neuro, Inc. (ALZN) is developing a comprehensive dementia therapy system by combining immunological methods and lithium-based developments for brain regeneration. A stable sales market is offset by the risks of logistical disruptions and the complexities of international patent protection. However, the business relies on a narrow range of drugs, creating a dependency on external financing. This historical price chart on GURU.Markets shows a value of -0.70.
Comprehensive metric breakdowns and analytics for Alzamend Neuro Inc. (ALZN)
- price and consensus price forecast:
- market capitalization details:
- book capitalization information:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Alzamend Neuro, Inc.|ALZN - Long-Term Debt to Capital|Current Liabilities to Capital alzamend.com|ALZN - Company Debts|Debt to Book Value Ratio Alzamend Neuro Inc.|ALZN - Company Long-Term Debts|Company Short-Term Indebtedness Alzamend Neuro|Intermediate Coverage Ratio alzamend.com
- net income and valuation multiples indicators:
ALZN - Company Net Income|Net Profit Forecast Alzamend Neuro, Inc.|ALZN - P/E Multiple|Projected Price to Earnings Ratio Alzamend Neuro|ALZN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Alzamend|ALZN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Alzamend Neuro|ALZN - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months alzamend.com|ALZN - Net earnings per share growth this year|Expected earnings per share trend next year Alzamend Neuro, Inc.
- company sales and revenue statistics:
Comprehensive company analysis:Alzamend Neuro ALZN
The P/E ratio reflects the market value of a business relative to its net income, measuring the payback period for investments. An increasing value signals expectations of expansion, while a decrease indicates undervaluation or stagnation. By analyzing the P/E multiple of a company, an investor identifies the gap between the speculative price and actual earnings. For Alzamend Neuro, Inc. (ALZN), this is critical, as the capitalization relies on the potential of LiPRO technology. The valuation reflects the market's confidence in the commercialization of a safe treatment for Alzheimer's disease.
Key competitors
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
